The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.